Regulatory
TLC announced financial results for the second quarter ended June 30, 2019, and provided a business update.
Hutchison China MediTech Limited announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs.
On July 18, it was reported by Reuters that Canada is opposed to any U.S. plans to buy Canadian prescription drugs because the country fears it will threaten its own drug supply or raise costs for its own people.
There were two issues the agency had. First, the FDA wanted the inclusion of two animal studies to evaluate whether the drug caused thickening of the heart valve. The second was more of a goof—the contract research organization Zogenix employed uploaded the wrong data set for the application.
MorphoSys AG will publish its first six months’ 2019 results on August 6, 2019 at 10:00pm CEST.
Galapagos NV announces its unaudited first half-year results, which are further detailed in its H1 2019 report available on the Galapagos website, www.glpg.com.
sterna biologicals selected as one of a group of top-tier European biotech companies to present at the European Biotech Investor Day on August 1, 2019 in New York City
Net sales increased 10 per cent compared to Q2 2018, corresponding to the net of acquisitions and discontinuing operations.
Delivered 31% increase in revenue, 51% increase in operating profit and 60% increase in net profit year-on-year Delivered 21% increase in revenue, with increases in operating profit and net profit compared to Q1 2019 Increased investment in pipeline to support long-term growth
FGFR inhibitor gains FDA approval based on 40% response rate in MD Anderson-led Phase II trial
PRESS RELEASES